NCT05822050

An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of PTCL

An Open, Single Center, Non-randomized, Single Arm Clinical Study of Evaluating the Efficacy of Selinexor in the Maintenance Treatment of Peripheral T-cell Lymphomas (PTCL)

• Status: Unknown
• Phase: Phase 2 / Phase 3
• Study type: Interventional
• Enrollment: 20 (estimated)
• Sponsor: The First Hospital of Jilin University · Academic / Other
• Sex: All
• Age: 18 Years – 85 Years
• Healthy volunteers: Not accepted

Summary

To evaluate the efficacy and safety of Selinexor maintenance therapy in PTCL patients who achieved complete response from frontline treatment, and to analyze the relationship between gene mutation in PTCL and disease prognosis and clinical features by using Next-generation sequencing (NGS) detection.

Conditions

• PTCL Patients Who Achieved Complete Response From Frontline Treatment

Interventions

Type	Name	Description
DRUG	Selinexor	XPO1 inhibitor

Timeline

• Start date: 2023-06-01
• Primary completion: 2024-12-31
• Completion: 2025-06-30
• First posted: 2023-04-20
• Last updated: 2023-08-03

Locations

1 site across 1 country: China